4503.T Astellas Pharma Inc.
Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism
Ten percent of the samples were saved for immunoblotting. The other 90% of samples were separated by SDS-PAGE, visualized by colloidal coomassie blue staining, destained and subjected to mass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback